Opportunity Information: Apply for PAR 18 513
The Alzheimer’s Clinical Trials Consortium (ACTC) Clinical Trials opportunity (PAR-18-513) is a National Institutes of Health (NIH) grant announcement that supports the design, launch, and execution of Phase I through Phase III clinical trials aimed at Alzheimer’s disease (AD) and other age-related dementias. The core purpose is to move promising interventions into well-run human studies that can show whether a treatment can prevent cognitive decline, delay the onset or progression of symptoms, or improve symptoms once they appear. The announcement explicitly allows both pharmacological approaches (for example, drugs or biologics) and non-pharmacological approaches (for example, behavioral, lifestyle, cognitive, device-based, or care-delivery interventions), as long as the project is a true clinical trial and fits within the early- to late-stage trial spectrum covered by Phases I to III.
A defining feature of this program is that applicants are expected to run their trials using the ACTC trial coordination and management infrastructure. In practical terms, that means the clinical trial is not envisioned as a standalone effort built from scratch at a single institution; instead, it is meant to leverage a dedicated consortium platform that can provide established operational support for things like trial start-up, site coordination, enrollment management, data collection and management, quality oversight, and general trial operations. The intent is to reduce redundancy, speed up trial implementation, and increase the consistency and rigor of AD and dementia trials by relying on a centralized, experienced clinical trials network.
The funding mechanism is the NIH R01, and the announcement states “Clinical Trial Required,” meaning the application must propose a clinical trial rather than only preclinical work, observational research, or trial planning without actual participant intervention and outcomes evaluation. The activity category is health, and the opportunity is listed under CFDA 93.866. While the summary information provided does not include an award ceiling or the number of expected awards, the emphasis is clearly on supporting interventional studies that are ready to be executed within the ACTC operational framework, rather than exploratory ideas that are not yet trial-ready.
Eligibility is broad and includes a wide range of domestic organizations: state, county, city, township, and special district governments; independent school districts; public housing authorities/Indian housing authorities; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; and Native American tribal organizations that are not federally recognized tribal governments. It also includes nonprofit organizations both with and without 501(c)(3) status (other than institutions of higher education), for-profit organizations (other than small businesses), and small businesses. The announcement also highlights additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, regional organizations, eligible federal agencies, U.S. territories or possessions, and even non-domestic (non-U.S.) entities (foreign organizations). Taken together, this suggests NIH is encouraging participation from a diverse set of institutions and communities, which is especially relevant in Alzheimer’s research where representative recruitment and inclusive trial access are longstanding needs.
Key administrative details in the source data include the original posting timeframe and close date: the FOA was created on 2017-12-18, and the original closing date listed is 2020-11-24. The awarding agency is NIH, and the instrument is a grant under a discretionary funding opportunity. Overall, the opportunity is best understood as a pathway for investigators and organizations to bring strong candidate interventions into rigorously managed clinical testing for Alzheimer’s disease and related dementias, using the established ACTC infrastructure to improve trial efficiency, consistency, and execution quality.Apply for PAR 18 513
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866.
- This funding opportunity was created on 2017-12-18.
- Applicants must submit their applications by 2020-11-24. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: Alzheimer’s Clinical Trials Consortium (ACTC) Clinical Trials Opportunity (PAR-18-513)
What is the ACTC Clinical Trials opportunity (PAR-18-513)?
PAR-18-513 is a National Institutes of Health (NIH) grant announcement that supports the design, launch, and execution of Phase I through Phase III clinical trials focused on Alzheimer’s disease (AD) and other age-related dementias.
What is the main goal of this funding opportunity?
The main goal is to move promising interventions into well-run human clinical studies to determine whether a treatment can prevent cognitive decline, delay the onset or progression of symptoms, or improve symptoms once they appear.
What types of studies does this FOA support?
This FOA supports true interventional clinical trials in humans, spanning early- to late-stage trials (Phase I, Phase II, and Phase III) for Alzheimer’s disease and other age-related dementias.
Are clinical trials required to apply?
Yes. The funding mechanism is designated as "Clinical Trial Required," meaning the application must propose an actual clinical trial rather than only preclinical research, observational studies, or trial planning that does not include participant intervention and outcomes evaluation.
Which trial phases are supported under this opportunity?
The opportunity supports Phase I through Phase III clinical trials.
What diseases or conditions are in scope?
The opportunity is aimed at Alzheimer’s disease (AD) and other age-related dementias.
What kinds of interventions are allowed?
Both pharmacological and non-pharmacological approaches are explicitly allowed, as long as the project is a true clinical trial and fits within Phase I to Phase III.
What are examples of pharmacological approaches that could fit?
Pharmacological approaches may include drugs or biologics, as described in the opportunity summary.
What are examples of non-pharmacological approaches that could fit?
Non-pharmacological approaches may include behavioral, lifestyle, cognitive, device-based, or care-delivery interventions, as described in the opportunity summary.
Does the trial have to be run through the Alzheimer’s Clinical Trials Consortium (ACTC)?
Yes. A defining feature of this program is that applicants are expected to run their trials using the ACTC trial coordination and management infrastructure rather than building a standalone trial operation from scratch.
What does it mean to use the ACTC infrastructure?
It means leveraging the consortium platform for established operational support such as trial start-up, site coordination, enrollment management, data collection and management, quality oversight, and general trial operations.
Why does this FOA emphasize using a centralized consortium infrastructure?
The stated intent is to reduce redundancy, speed up trial implementation, and increase consistency and rigor across Alzheimer’s disease and dementia clinical trials by relying on a centralized, experienced clinical trials network.
What is the NIH funding mechanism for PAR-18-513?
The funding mechanism is the NIH R01.
What is the awarding agency?
The awarding agency is the National Institutes of Health (NIH).
What is the assistance listing / CFDA number for this opportunity?
The opportunity is listed under CFDA 93.866.
What is the activity category?
The activity category is health.
Is this opportunity considered a discretionary grant program?
Yes. It is described as a grant under a discretionary funding opportunity.
Who is eligible to apply?
Eligibility is broad and includes a wide range of domestic organizations (including various levels of government, eligible public entities, higher education institutions, nonprofits, and businesses) and also includes non-domestic (non-U.S.) entities (foreign organizations), as stated in the opportunity summary.
Are state and local governments eligible?
Yes. Eligible government entities include state governments; county, city, township, and special district governments; and public housing authorities/Indian housing authorities.
Are schools and universities eligible?
Yes. Eligibility includes independent school districts, public and state-controlled institutions of higher education, and private institutions of higher education.
Are tribal entities eligible to apply?
Yes. Eligibility includes federally recognized Native American tribal governments and Native American tribal organizations that are not federally recognized tribal governments.
Are nonprofits eligible?
Yes. Eligibility includes nonprofit organizations with and without 501(c)(3) status (other than institutions of higher education).
Are for-profit organizations eligible?
Yes. For-profit organizations (other than small businesses) are eligible, and small businesses are also eligible.
Are faith-based or community-based organizations eligible?
Yes. The opportunity highlights faith-based or community-based organizations as eligible applicants.
Are minority-serving institutions specifically included?
Yes. The opportunity highlights Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs) as eligible applicants.
Are U.S. territories or possessions eligible?
Yes. U.S. territories or possessions are listed among eligible applicants.
Are foreign (non-U.S.) organizations eligible to apply?
Yes. The opportunity summary explicitly includes non-domestic (non-U.S.) entities (foreign organizations).
Does the summary list an award ceiling or the expected number of awards?
No. The provided summary information does not include an award ceiling or the number of expected awards.
What kinds of projects are emphasized as a good fit?
The emphasis is on interventional studies that are ready to be executed within the ACTC operational framework, rather than exploratory ideas that are not yet trial-ready.
When was this FOA created and what close date is listed?
The FOA was created on 2017-12-18, and the original closing date listed is 2020-11-24.
Is a single-institution standalone trial the intended model for this opportunity?
No. The trial is not envisioned as a standalone effort built from scratch at a single institution; it is meant to leverage the ACTC consortium platform for coordination and operational support.
Browse more opportunities from the same category: Health
Next opportunity: NIH StrokeNet Small Business Innovation Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (U44 - Clinical Trials Optional)
Previous opportunity: Ukraine: U.S. government Public Diplomacy Small Grants Program – Education and Culture
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 18 513
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 18 513) also looked into and applied for these:
| Funding Opportunity |
|---|
| Health-professional Education Partnership Initiative (HEPI) (R25 Clinical Trial Not Allowed) Apply for RFA TW 17 001 Funding Number: RFA TW 17 001 Agency: National Institutes of Health Category: Health Funding Amount: $600,000 |
| Effects of In Utero Alcohol Exposure on Adult Health and Disease (R01 - Clinical Trial Optional) Apply for PA 18 507 Funding Number: PA 18 507 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Consequences of amyloid protein polymorphisms in Alzheimer's disease (R01 - Clinical Trial Not Allowed) Apply for RFA AG 18 025 Funding Number: RFA AG 18 025 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| NEI Collaborative Clinical Vision Project: Resource Center Grant (UG1- Clinical Trial Required) Apply for PAR 18 522 Funding Number: PAR 18 522 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Effects of In Utero Alcohol Exposure on Adult Health and Disease (R21 - Clinical Trial Optional) Apply for PA 18 508 Funding Number: PA 18 508 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| CREATE Bio Development Track: Preclinical and Early-Phase Clinical Development for Biologics (U44 SBIR- Clinical Trial Optional) Apply for PAR 18 543 Funding Number: PAR 18 543 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases (U01) Apply for PAR 18 534 Funding Number: PAR 18 534 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Human Cell Biology of Alzheimer's Disease Genetic Variants (R01 - Clinical Trial Not Allowed) Apply for PAR 18 516 Funding Number: PAR 18 516 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NEI Collaborative Clinical Vision Research Project: Coordinating Center Grant (UG1 Clinical Trial Required) Apply for PAR 18 521 Funding Number: PAR 18 521 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Radiological/Nuclear Medical Countermeasure Product Development Program (SBIR) (R43/R44 Clinical Trial Not Allowed) Apply for PA 18 525 Funding Number: PA 18 525 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NEI Collaborative Clinical Vision Research : Chair's Grant (UG1-Clinical Trial Required) Apply for PAR 18 523 Funding Number: PAR 18 523 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Sensory and motor system changes as predictors of preclinical Alzheimers disease (R01 - Clinical Trial Not Allowed) Apply for PAR 18 519 Funding Number: PAR 18 519 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS CREATE Bio Development Track: Preclinical Development for Biotechnology Products and Biologics (U01 - Clinical Trial Optional) Apply for PAR 18 542 Funding Number: PAR 18 542 Agency: National Institutes of Health Category: Health Funding Amount: $1,500,000 |
| NeuroNEXT Clinical Trials (U01 - Clinical Trial Optional) Apply for PAR 18 528 Funding Number: PAR 18 528 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCD Research Grants for Translating Basic Research into Clinical Tools (R01- Clinical Trials Optional) Apply for PAR 18 533 Funding Number: PAR 18 533 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Understanding the Effects of ApoE2 on the Interaction between Aging and Alzheimers Disease (R01 - Clinical Trial Not Allowed) Apply for RFA AG 18 022 Funding Number: RFA AG 18 022 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Institutional Training Programs to Advance Translational Research on Alzheimer's Disease and AD Related Dementias (T32 - Clinical Trial Not Allowed) Apply for PAR 18 524 Funding Number: PAR 18 524 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3) - Clinical Trial Required Apply for PAR 18 547 Funding Number: PAR 18 547 Agency: National Institutes of Health Category: Health Funding Amount: $400,000 |
| Basic and Translation Research on Decision Making in Aging and Alzheimer's Disease (R21 - Clinical Trial Optional) Apply for PAR 18 538 Funding Number: PAR 18 538 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Basic and Translational Research on Decision Making in Aging and Alzheimer's Disease (R01 - Clinical Trial Optional) Apply for PAR 18 544 Funding Number: PAR 18 544 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 18 513", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.